BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 17914921)

  • 1. Combination antifungals: an update.
    Segal BH; Steinbach WJ
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):883-92. PubMed ID: 17914921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision making in antifungal monotherapy versus combination therapy.
    Lewis RE
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):61S-67S. PubMed ID: 16716124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological advances in the treatment of invasive candidiasis.
    Deck DH; Guglielmo BJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):137-49. PubMed ID: 16441215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fungicidal versus Fungistatic: what's in a word?
    Lewis JS; Graybill JR
    Expert Opin Pharmacother; 2008 Apr; 9(6):927-35. PubMed ID: 18377336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward more effective antifungal therapy: the prospects of combination therapy.
    Kontoyiannis DP; Lewis RE
    Br J Haematol; 2004 Jul; 126(2):165-75. PubMed ID: 15238137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on antifungal treatment of invasive Candida and Aspergillus infections.
    Maschmeyer G; Ruhnke M
    Mycoses; 2004 Aug; 47(7):263-76. PubMed ID: 15310328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in antifungal chemotherapy.
    Petrikkos G; Skiada A
    Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on echinocandin antifungals.
    Kauffman CA; Carver PL
    Semin Respir Crit Care Med; 2008 Apr; 29(2):211-9. PubMed ID: 18366002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinatorial strategies for combating invasive fungal infections.
    Spitzer M; Robbins N; Wright GD
    Virulence; 2017 Feb; 8(2):169-185. PubMed ID: 27268286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antifungal therapy: a critical review of the evidence.
    Ostrosky-Zeichner L
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():65-70. PubMed ID: 18430131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric antifungal therapy. Part I: focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients.
    Allen U; Bow E; Doyle J; Richardson S; Robinson J; Rotstein C; Davies D; Hui C; Le Saux N; Laverdiere M; Read S
    Minerva Pediatr; 2010 Feb; 62(1):57-69. PubMed ID: 20212399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic implications for use of antifungal agents.
    Lewis RE
    Curr Opin Pharmacol; 2007 Oct; 7(5):491-7. PubMed ID: 17616480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida resistance and its clinical relevance.
    Klepser ME
    Pharmacotherapy; 2006 Jun; 26(6 Pt 2):68S-75S. PubMed ID: 16716125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fungal infections in the immunocompromised host.
    Hawkins C; Armstrong D
    Clin Haematol; 1984 Oct; 13(3):599-630. PubMed ID: 6388935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances and challenges in the treatment of invasive fungal infections.
    Shao PL; Huang LM; Hsueh PR
    Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.
    Steinbach WJ; Stevens DA
    Clin Infect Dis; 2003 Oct; 37 Suppl 3():S157-87. PubMed ID: 12975751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for invasive mycoses: evaluation of past clinical trial designs.
    Sobel JD
    Clin Infect Dis; 2004 Oct; 39 Suppl 4():S224-7. PubMed ID: 15546122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echinocandins: a wealth of choice--how clinically different are they?
    Zaas AK
    Curr Opin Infect Dis; 2008 Aug; 21(4):426-32. PubMed ID: 18594297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of a new polyene SPK-843 against Candida spp, Cryptococcus neoformans and Aspergillus spp clinical isolates.
    Kantarcioglu AS; Yucel A; Vidotto V
    J Chemother; 2003 Jun; 15(3):296-8. PubMed ID: 12868560
    [No Abstract]   [Full Text] [Related]  

  • 20. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB; Sujatha S; Parija SC
    Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.